M H Kyaw1, I G Jones, H Campbell. 1. University of Edinburgh, Public Health Sciences, Scotland. Moe.Kyaw@scieh.csa.scot.nhs.uk
Abstract
UNLABELLED: Pneumococcal disease is a major cause of morbidity and mortality in infants and young children worldwide. New pneumococcal conjugate vaccines include 7 to 11 serotypes, which are the most common cause of paediatric disease in most parts of the world. The efficacy of a 7-valent conjugate vaccine was 97.4% (95% CI, 82.7-99.9) against invasive pneumococcal disease, and 57% (95% CI, 44-67) against otitis media, caused by vaccine serotypes. Evidence shows that the vaccine has the potential to prevent pneumonia. Pneumococcal conjugate vaccination has also been shown to reduce nasopharyngeal carriage of vaccine serotypes (particularly serotypes associated with antibiotic resistance). Thus widespread use of pneumococcal conjugate vaccine could substantially reduce the burden of invasive disease and would have the potential to control the global spread of antibiotic resistance in pneumococci. CONCLUSION: It is important that these highly effective vaccines should be made available to children in the developing countries.
UNLABELLED: Pneumococcal disease is a major cause of morbidity and mortality in infants and young children worldwide. New pneumococcal conjugate vaccines include 7 to 11 serotypes, which are the most common cause of paediatric disease in most parts of the world. The efficacy of a 7-valent conjugate vaccine was 97.4% (95% CI, 82.7-99.9) against invasive pneumococcal disease, and 57% (95% CI, 44-67) against otitis media, caused by vaccine serotypes. Evidence shows that the vaccine has the potential to prevent pneumonia. Pneumococcal conjugate vaccination has also been shown to reduce nasopharyngeal carriage of vaccine serotypes (particularly serotypes associated with antibiotic resistance). Thus widespread use of pneumococcal conjugate vaccine could substantially reduce the burden of invasive disease and would have the potential to control the global spread of antibiotic resistance in pneumococci. CONCLUSION: It is important that these highly effective vaccines should be made available to children in the developing countries.
Authors: Kam Lun Hon; Margaret Ip; Kenneth Lee; Edmund Anthony Nelson; Ka Ho Eric Shea; Yiu Sang Tony Yuen; Ting Fan Leung Journal: Indian J Pediatr Date: 2010-09-16 Impact factor: 1.967
Authors: Branda T Hu; Xinhong Yu; Thomas R Jones; Carol Kirch; Sarah Harris; Stephen W Hildreth; Dace V Madore; Sally A Quataert Journal: Clin Diagn Lab Immunol Date: 2005-02